Skip to main content
. 2020 Oct 9;21(20):7451. doi: 10.3390/ijms21207451

Figure 5.

Figure 5

Human vitreous levels of eicosanoids in PDR subtypes treated with bevacizumab, VH (n = 11) vs. TRD (n = 8) eyes. Comparison of levels (pg/mL) of 5-HETE, 12-HETE, 15-HETE, 12-HETrE, and 19-HETE in VH vs. TRD.